Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platform theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
(0)
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 /
Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the Company ) has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange. The Company, its Board, advisors and management team are going to devote resources to accomplish this as swiftly as possible. We are delighted to have submitted the initial application and will work through the process utilizing all resources to our disposal.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK:ONPH) (the Company ) is currently engaging in research and development of therapeutics for oncology and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
Oncology Pharma, Inc. Has Submitted Its Initial Application to List the Company on the Capital Markets Tier of the NASDAQ Exchange
ACCESSWIRE
SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2021 /
Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the Company ) has submitted its initial application to the NASDAQ to begin the process of moving the listing from the Pink Sheets to the Capital Markets Tier of the NASDAQ Exchange. The Company, its Board, advisors and management team are going to devote resources to accomplish this as swiftly as possible. We are delighted to have submitted the initial application and will work through the process utilizing all resources to our disposal.
(1)
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 /
Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient s own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.
Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer
ACCESSWIRE
SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2021 /
Oncology Pharma Inc. (OTC PINK:ONPH) ONPH has entered into a licensing agreement with Regen BioPharma, Inc. for a technology utilizing small molecules to activate immune checkpoints for the treatment of colon cancer. The program entails identifying small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially critical immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, one can unleash the cancer-killing potential of a patient s own immune system. Regen is also engaged in the identification of small molecules which activate the NR2F6 nuclear receptor that can be utilized to develop small molecule therapies for autoimmune disorders.